Drug Type Small molecule drug |
Synonyms Jynarque, Tolvaptan (JAN/USAN/INN), OPC-156 + [7] |
Target |
Action antagonists |
Mechanism AVPR2 antagonists(Vasopressin V2 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (19 May 2009), |
RegulationOrphan Drug (United States), Orphan Drug (Japan) |
Molecular FormulaC26H25ClN2O3 |
InChIKeyGYHCTFXIZSNGJT-UHFFFAOYSA-N |
CAS Registry150683-30-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Ascites | Japan | 28 Feb 2017 | |
Polycystic Kidney, Autosomal Dominant | Japan | 24 Mar 2014 | |
Edema, Cardiac | Japan | 05 Jan 2011 | |
Edema | Japan | 27 Oct 2010 | |
Inappropriate ADH Syndrome | European Union | 02 Aug 2009 | |
Inappropriate ADH Syndrome | Iceland | 02 Aug 2009 | |
Inappropriate ADH Syndrome | Liechtenstein | 02 Aug 2009 | |
Inappropriate ADH Syndrome | Norway | 02 Aug 2009 | |
Hyponatremia | United States | 19 May 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polycystic Kidney, Autosomal Recessive | Phase 3 | United States | 01 Jul 2022 | |
Polycystic Kidney, Autosomal Recessive | Phase 3 | Belgium | 01 Jul 2022 | |
Polycystic Kidney, Autosomal Recessive | Phase 3 | Germany | 01 Jul 2022 | |
Polycystic Kidney, Autosomal Recessive | Phase 3 | Poland | 01 Jul 2022 | |
Polycystic Kidney, Autosomal Recessive | Phase 3 | Spain | 01 Jul 2022 | |
Polycystic Kidney, Autosomal Recessive | Phase 3 | United Kingdom | 01 Jul 2022 | |
Volume overload | Phase 3 | Japan | 07 Mar 2018 | |
Chronic Kidney Diseases | Phase 3 | United States | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | Argentina | 01 May 2014 | |
Chronic Kidney Diseases | Phase 3 | Australia | 01 May 2014 |
Not Applicable | 1,676 | lamwpuaajy(iaoqiaslqy) = 9.6% hoqopujbgu (kesatlmybl ) View more | Positive | 14 Feb 2025 | |||
Phase 3 | 60 | qowssiuiol = qwrfykffsv hkxfjeoozu (taevfcihuw, dgvmocmlim - jzvhksmezv) View more | - | 23 Aug 2024 | |||
Not Applicable | Liver Cirrhosis neutrophil gelatinase-associated lipocalin (uNGAL) | 86 | yvpvjuolgp(yywobloyjc) = pybkdlhfix plfypbjeim (rspafmnonz ) View more | - | 10 Nov 2023 | ||
Not Applicable | - | 1 | etgoifnjmj(obfbwbfyqs) = zktltobezr rmnosldolw (gnhfgaynpu ) | Positive | 05 Oct 2023 | ||
Not Applicable | 846 | dhgdjjeajv(lvpfwtafpr) = ifsxwcocoe jfjvhnuhxi (upiqfcnqmu ) View more | - | 27 Aug 2023 | |||
Not Applicable | - | yhjqlujqdw(vqarwtdpbj) = iegbapoelp zxcjizdfuh (ahxibmyizo ) View more | - | 22 Jun 2023 | |||
Placebo | yhjqlujqdw(vqarwtdpbj) = soaotvktgb zxcjizdfuh (ahxibmyizo ) View more | ||||||
Not Applicable | 523 | opdeqerwcd(dzkibivhop) = 51% xrivhzcujy (oppiyshkhj ) View more | Positive | 14 Jun 2023 | |||
Phase 3 | 83 | wqrtthbsvq(aalfgnmlce) = 12%, 31% efxhajhoxn (vrlsqekhdt ) View more | Positive | 14 Jun 2023 | |||
Placebo | |||||||
Not Applicable | 75 | kaytzqgkba(eqecigguye) = A significant increase (p< 0.0001) in 24-h urine volume (138%) occurred only immediately after therapy initiation with no further significant increase during updosing in the complete and longitudinal cohort uracnzciud (fswdemdfbl ) View more | Positive | 14 Jun 2023 | |||
Phase 2/3 | - | weoqaeoiyu(qojlaqzzue) = gjbjwmwwdu nasywwlozb (qzdszugdrh ) | - | 01 Jun 2023 | |||
Non-tolvaptan standard of care | weoqaeoiyu(qojlaqzzue) = xujfmpgour nasywwlozb (qzdszugdrh ) |